Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survey Assesses Approaches to Extreme Thrombocytosis

Ann Hematol; 2017 Jan; Koren-Michowitz, et al

Publish date:: January 29, 2017

There is lack of consensus on how to manage patients with myeloproliferative neoplasms (MPNs) and extreme thrombocytosis, according to a survey involving 90 physicians.

Investigators sent questionnaires to 202 members of MPN working groups; 45% responded. Respondents were asked to consider their approach to these cases: low thrombotic risk essential thrombocythemia (ET) with either JAK2V617F or CALR mutation; polycythemia vera with ExT either with or without leukocytosis; an ET patient needing urgent orthopedic surgery; and a poorly controlled ET patient with acute cerebral venous sinus thrombosis. Among the results:

Treatment of asymptomatic JAK2V617F positive ET and target platelet count on cytoreduction were significantly influenced by physician years of experience.
Responses were not influenced by the volume of MPN practice or by whether MPN was considered a major interest by the physician.

Citation:

Koren-Michowitz M, Lavi N, Ellis M, Vannucchi A, Mesa R, Harrison C. Management of extreme thrombocytosis in myeloproliferative neoplasms: An international physician survey. Ann Hematol. 2017;96(1):87-92. doi:10.1007/s00277-016-2826-4.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al